NCT00602342已完成不适用
A Single Dose, Two-Period, Two-Treatment, 2-Way Crossover Bioequivalency Study of 250 mg Terbinafine Hydrochloride Tablets Under Fasting Conditions
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- Bioequivalence
研究概览
简要总结
The objective of this study was the bioequivalence of a Roxane Laboratories' terbinafine tablets, 250 mg, to Lamisil® Tablets, 250 mg (Novartis Pharmaceutical Corporation.) under fasting conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening.
排除标准
- •Positive test for HIV, Hepatitis B, or Hepatitis C.
- •Treatment with known enzyme altering drugs.
- •History of allergic or adverse response to terbinafine or any comparable or similar product.
结局指标
主要结局
Bioequivalence
时间窗: Baseline, Two period, Twenty-one day washout
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Bioequivalency Study of Terbinafine Tablets Under Fed ConditionsOnychomycosisNCT00602251Roxane Laboratories30
已完成
1 期
Bioequivalence Study for Terbinafine 250 mgMycosesNCT01772212GlaxoSmithKline30
已完成
不适用
Bioequivalency Study of Torsemide Tablets Under Fed ConditionsEdemaNCT00602615Roxane Laboratories28
已完成
不适用
Bioequivalency Study of Torsemide Tablets Under Fasting ConditionsEdemaNCT00602303Roxane Laboratories28
已完成
不适用
Bioequivalency Study of 5 mg Pilocarpine Tablets Under Fasting ConditionsDry MouthNCT00601874Roxane Laboratories28